Biovica announces the start of the TK IMPACT trial at Washington University of St Louis

Biovica, active in cancer diagnostics, today announces initiation of the TK IMPACT study, an investigator initiated prospective clinical trial at Washington University of St Louis to evaluate the clinical utility of Biovica’s blood-based biomarker assay DiviTum®TKa on monitoring practices in the care of metastatic breast cancer patients.

2021-11-24T08:00:00+01:00November 24th, 2021 08:00|

Biovica meddelar start av TK IMPACT studien vid Washington University of St Louis

Biovica , verksamt inom cancerdiagnostik, meddelar idag att bolaget TK IMPACT studien startar, en prövarinitierad prospektiv klinisk studie vid Washington University of St Louis som utvärderar den kliniska användbarheten av Biovicas blodbaserade biomarkörstest DiviTum®TKa vid monitorering av patienter med spridd bröstcancer.

2021-11-24T08:00:00+01:00November 24th, 2021 08:00|

Tre studier av Biovicas DiviTum®TKa presenteras på SABCS 2021

Biovica, verksamt inom cancerdiagnostik, meddelar idag att resultaten från tre studier med DiviTum®TKa, inklusive en budgeteffektmodell, kommer att presenteras vid världens största bröstcancerkonferens, San Antonio Breast Cancer Symposium (SABCS), i början av december. Studierna omfattar nästa generations CDK-hämmare, samuraciclib från Carrick Therapeutics, biomarkörstudien PROMISE utförd vid Mayo Clinic och DiviTum®TKas budgeteffektmodell. Alla studier fokuserar på DiviTum®TKas roll vid monitorering av behandling av spridd bröstcancer.

2021-11-19T16:05:00+01:00November 19th, 2021 16:05|

Biovica’s DiviTum®TKa in three studies at SABCS 2021

Biovica, active in cancer diagnostics, today announced that results from three different studies using DiviTum®TKa, including a budget impact model, will be presented at the world's largest breast cancer symposium, San Antonio Breast Cancer Symposium (SABCS), in early December. The studies are of a next generation CDK inhibitor, samuraciclib from Carrick Therapeutics, the biomarker study PROMISE performed at the Mayo Clinic, and the DiviTum®TKa budget impact model. All studies focused on the role of DiviTum®TKa in monitoring treatment in women with metastatic breast cancer.

2021-11-19T16:05:00+01:00November 19th, 2021 16:05|

Biovica’s DiviTum®TKa results published in Journal of Medical Economics

Biovica, active in cancer diagnostics, today announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics. This publication expands on data presented at the ISPOR 2021 meeting. The model’s results show that monitoring with DiviTum®TKa may achieve savings of up to three times the extra spend relative to current management of metastatic breast cancer patients.

2021-11-16T09:15:00+01:00November 16th, 2021 09:15|

Biovicas DiviTum®TKa-resultat publicerade i Journal of Medical Economics

Biovica, verksamt inom cancerdiagnostik, meddelade idag att resultaten av en DiviTum®TKa-budgetmodell har publicerats i Journal of Medical Economics. Publikationen utökar de data som presenterades vid ISPOR 2021. Resultaten från modellen visar att monitorering med DiviTum®TKa kan ge besparingar på upp till tre gånger den extra kostnaden jämfört med nuvarande behandling av patienter med spridd bröstcancer.

2021-11-16T09:15:00+01:00November 16th, 2021 09:15|